Antibody Drug Conjugate (ADC) for TNBC

Triple-negative breast cancer (TNBC) accounts for approximately 10 to 15 percent of all breast cancers. In triple-negative breast cancer (TNBC), the unhealthy cells typically don’t have estrogen or progesterone receptors (ER or PR) and they create very little or none of the human epidermal growth factor receptor 2 (HER2) protein. Antibody-drug conjugate (ADC): An antibody-drug conjugate […]